ALLURION TECHNOLOGIES INC

Company Overview

Allurion Technologies is a medical device and digital therapeutics company focused on an end-to-end weight‑loss platform built around the swallowable, procedureless Allurion Balloon and the Allurion Virtual Care Suite (VCS). Commercial outside the U.S. since 2016, it sells a B2B2C bundle (balloon, connected scale, wearables, digital coaching) via a direct salesforce and distributors and manufactures assembly in‑house in Natick, MA. Recent strategic shifts include a U.S. VCS launch, AllurionMeds (lower‑dose GLP‑1 combined with digital care), positive AUDACITY pivotal topline results and an impending FDA PMA submission, but the company faces steep revenue declines (2024), constrained liquidity, workforce reductions and financing/covenant arrangements with RTW. R&D, regulatory milestones and reimbursement/provider adoption are central to its commercial outlook and risk profile.

Executive Compensation Practices

Given Allurion’s early‑commercial, clinical‑milestone driven profile, executive pay is likely to be equity‑heavy with lower base cash and significant performance‑based long‑term incentives tied to FDA/PMA progress, clinical outcomes (AUDACITY results), revenue thresholds and distributor adoption metrics. The company’s recent cash constraints and explicit going‑concern disclosures mean management is likely to favor stock options, restricted stock units with milestone vesting, and earnouts/contingent awards over large cash bonuses to preserve liquidity. Cost‑cutting, restructuring severance and RTW’s governance/equity stake also increase the probability of retention awards or accelerated vesting for key executives; compensation committees may link incentives to gross margin improvement and successful commercial scaling to reduce per‑unit manufacturing costs. Finally, fair‑value volatility from warrants, convertibles and revenue‑interest financing will affect reported compensation expense and the economic value executives realize from equity awards.

Insider Trading Considerations

Material clinical and regulatory events (PMA submission, AUDACITY supplemental analyses, FDA decisions) are the primary drivers of material non‑public information — insiders will be subject to strict blackout windows and should commonly use 10b5‑1 plans to manage trading risk around these milestones. Because insiders may hold a mix of common shares, options, warrants and convertible securities (and because recent financing rounds and RTW conversions materially altered capitalization), reported insider transactions can signal dilution, financing activity or covenant pressures rather than pure sentiment about operations. Restructuring‑related severance, retention‑award vesting and contractual transfer or conversion mechanics under the Omnibus Amendment can create clustered insider sales around financing or milestone dates; traders should treat clustered filings with caution and cross‑check Section 16 filings, Form 4 timing, and any related PIPE/conversion press releases. Finally, regulatory and contractual covenants (minimum cash, trailing revenue and FDA milestones) increase the likelihood of opportunistic financing and related insider activity — so track insider trades in the context of covenant deadlines and public updates on PMA/reimbursement progress.